Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID-19 severe or critically meta-analysis

Cao
  ChiCTR2000029308		 RCTlopinavir/ritonavirstandard of careCOVID-19 severe or criticallysome concern
99/100 suggested
  • inconclusive 31 % increase in clinical improvement,clinical improvement (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
  • suggested 94 % increase in clinical improvement (14-day) with a moderate degree of certainty due to some concern in risk of bias
COALITION II Covid-19 Brazil (Furtado)
  NCT04321278		 RCTazithromycinstandard of careCOVID-19 severe or criticallysome concern
214/183 safety concern
  • inconclusive 26 % decrease in clinical improvement,clinical improvement (14-day) (PE) with a moderate degree of certainty due to some concern in risk of bias
  • statistically significant 6 % decrease in clinical improvement (7-day) with a moderate degree of certainty due to some concern in risk of bias
REMAP-CAP (lopinavir/ritonavir only)
  NCT02735707		 RCTlopinavir/ritonavirstandard of careCOVID-19 severe or criticallysome concern
268/377 safety concern
  • statistically significant 17 % decrease in hospital discharge with a moderate degree of certainty due to some concern in risk of bias
REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine)
  NCT02735707		 RCTLopinavir/ritonavir plus hydroxychloroquinestandard of careCOVID-19 severe or criticallysome concern
29/377 safety concern
  • suggested 42 % decrease in deaths,deaths (time to event analysis only) with a moderate degree of certainty due to some concern in risk of bias
  • statistically significant 37 % decrease in hospital discharge with a moderate degree of certainty due to some concern in risk of bias
1 study excluded by filtering options (0 RCT / 1 OBS)

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons